Sandip Datta received his M.D. from University of California, San Francisco, and completed his residency in Internal Medicine and fellowship in Infectious Diseases at University of California, San Diego. He trained in the laboratory of Eyal Raz at UCSD, where he was appointed Assistant Professor in 2004. From 2008 to 2017, he was a Clinical Investigator and Head of the Bacterial Pathogenesis Unit in the Laboratory of Clinical Infectious Diseases at NIH/NIAID, where his research focused on host defense against bacteria, with a particular emphasis on the human pathogen Staphylococcus aureus. His laboratory used cellular, animal model, and patient-based studies to investigate how interactions between the host immune system, the pathogen, and the commensal microbiota shape responses to infection and vaccination. From 2017 to 2020, Dr. Datta was at Merck Research Laboratories (Merck & Co, Inc) in Boston as Prinicpal Scientist and Clinical Director in Translational Pharmacology, guiding early clinical development of drugs and vaccines. From 2020 to 2024, Dr. Datta was at Johnson and Johnson Innovative Medicine (formerly Janssen Pharmaceuticals) in Cambridge, Massachusetts, seving in capacities as Senior Director of Early Development, Infectious Diseases and Vaccines and Senior Director of Translational Science in Immunology. In 2024, Dr. Datta joined Aditum Bio as Vice President of Medical.